Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Strategies Proposed to Improve Management of Immune-Related Adverse Events

January 11, 2021
By Hannah Slater
News
Article

Though the majority of immune-related adverse events (irAEs) can be managed with corticosteroids and other immunosuppressive treatments, life-threatening and sometimes fatal events have still been reported thus revealing a need to develop measures for effective management.

In a paper published in the Journal for ImmunoTherapy of Cancer, researchers investigators proposed a variety of strategies seeking to improve the management of immune-related adverse events (irAEs) brought on by immune checkpoint inhibitors.

Distinct from conventional cancer treatments that act on tumor growths directly, immune checkpoint inhibitors work by restoring the suppressed immune system in order to attack tumor cells. Nonetheless, by disrupting the homeostatic mechanisms that balance immune cell functions, immune checkpoint inhibitors prompt irAEs in a significant proportion of patients.

Though the majority of irAEs can be managed with immunosuppressive treatments, life-threatening and sometimes fatal events have still been known to occur in patients receiving these therapies. Moreover, without predictive biomarkers to determine which patients are at risk for irAEs or standardized approaches for detection, reporting, and treatment of irAEs, management has proven challenging. These factors taken together suggesting a need to develop strategies that will improve the handling of irAEs.

Importantly though, the incidence of irAEs is largely dependent on the type of immune checkpoint inhibitor used; for example, patients treated with the CTLA-4 inhibitor ipilimumab (Yervoy) experience irAEs at a rate of up to 70% versus around 30% for those treated with a PD-1 inhibitor. The highest incidence of events has been reported in those receiving the CTLA-4/PD-1 inhibitor combination of ipilimumab plus nivolumab (Opdivo). Similarly, the severity and type of irAEs differs with each checkpoint inhibitor used.

“With increasing use of [immune checkpoint inhibitors] for treatment of various cancers, the incidence of irAEs will undoubtedly increase,” the study authors who were led by Aung Naing, MD, wrote in their paper. “There is a compelling need to develop measures to effectively manage irAEs, both in the community settings and in cancer centers alike.”

In order to address the current unmet need in this area, investigators recommended a variety of measures for the effective management of irAEs including. Strategies recommended for the effective management of irAEs included:

  • Implementing patient education resources tailored to the individual needs of the patient in order to enhance awareness and thoughtful conversation
  • Clarifying guidelines for the management of irAEs and regularly convening a summit to revise the guidelines as needed
  • Adding more terms to the Common Terminology Criteria for Adverse Events (CTCAE) for standardized capture of all irAEs
  • Optimizing the choice, dosing, and duration of use of immunosuppressive agents for the management of irAEs
  • Seeking to better understand irAEs and their possible association with treatment outcomes through more preclinical, translational, and clinical studies
  • Incorporating high-risk patients into studies of immune checkpoint inhibitors and establishing a national registry of these patients
  • Integrating the use of diagnostic tools to personalize the management of irAEs and aid in facilitating decision making
  • Equipping health care providers with wireless technology and digital resources
  • Producing a platform to ensure the missing patient’s voice is heard
  • Disseminating evolving data to the scientific community promptly in order to expedite the translation of research results

“By adopting strategies such as listening to patients’ voices, conducting preclinical, clinical, and translational studies to identify predictive markers of irAEs, and developing evidence-based irAE management guidelines, we can minimize the toxic effects of [immune checkpoint inhibitors] while achieving the full therapeutic potential of these drugs,” concluded the authors.

Reference:

Naing A, Hajjar J, Gulley JL, et al. Strategies for improving the management of immune-related adverse events. Journal for ImmunoTherapy of Cancer 2020;8(2):e001754. doi:10.1136/jitc-2020-001754

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Leadership of a new cancer center as part of JFK University Medical Center discuss how they can support frontline clinicians.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Related Content

Workplace Burnout Among Oncologists Has Risen: What Can Be Done?

Workplace Burnout Among Oncologists Has Risen: What Can Be Done?

Tim Cortese
May 5th 2025
Article

Results from a recent survey showed that 20% of oncologists planned to reduce their hours in the next 12 months, as workplace burnout among them has increased.


Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.


Organ Preservation Noted With Neoadjuvant Dostarlimab in dMMR Tumors

Organ Preservation Noted With Neoadjuvant Dostarlimab in dMMR Tumors

Caroline Seymour
April 29th 2025
Article

A phase 2 study found a complete clinical response of 82% with neoadjuvant dostarlimab in dMMR solid tumors.


Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.


Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

FDA Rejects Breakthrough Designation, Approval for Itolizumab in Acute GVHD

Roman Fabbricatore
April 25th 2025
Article

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.


FDA Clears IND for VS-7375 in KRAS G12D-Mutated Advanced Solid Tumors

FDA Clears IND for VS-7375 in KRAS G12D-Mutated Advanced Solid Tumors

Tim Cortese
April 24th 2025
Article

The clearance precedes the initiation of a phase 1/2a trial that will evaluate the efficacy and safety of VS-7375 in advanced solid tumors with a KRAS-G12D mutation.

Related Content

Workplace Burnout Among Oncologists Has Risen: What Can Be Done?

Workplace Burnout Among Oncologists Has Risen: What Can Be Done?

Tim Cortese
May 5th 2025
Article

Results from a recent survey showed that 20% of oncologists planned to reduce their hours in the next 12 months, as workplace burnout among them has increased.


Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.


Organ Preservation Noted With Neoadjuvant Dostarlimab in dMMR Tumors

Organ Preservation Noted With Neoadjuvant Dostarlimab in dMMR Tumors

Caroline Seymour
April 29th 2025
Article

A phase 2 study found a complete clinical response of 82% with neoadjuvant dostarlimab in dMMR solid tumors.


Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.


Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

FDA Rejects Breakthrough Designation, Approval for Itolizumab in Acute GVHD

Roman Fabbricatore
April 25th 2025
Article

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.


FDA Clears IND for VS-7375 in KRAS G12D-Mutated Advanced Solid Tumors

FDA Clears IND for VS-7375 in KRAS G12D-Mutated Advanced Solid Tumors

Tim Cortese
April 24th 2025
Article

The clearance precedes the initiation of a phase 1/2a trial that will evaluate the efficacy and safety of VS-7375 in advanced solid tumors with a KRAS-G12D mutation.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.